Jaguar Health to present crofelemer open-label results at ACG Oct 9-14, 2026

Jaguar Health said preliminary results from an ongoing open-label crofelemer study in adult SBS-IF patients will be presented at the American College of Gastroenterology Annual Scientific Meeting on Oct. 9-14, 2026. It also plans to report Phase 2 placebo-controlled trial results in adult Type 1 short bowel syndrome patients in 2H 2027 and is targeting a mid-2027 NDA filing for microvillus inclusion disease.